

AGENDA

De novo Metastatic Hormone-Sensitive Prostate Cancer/ (mHSPC)

June 24, 2021

5 PM ET



LUGPA
Integrated Practices
Comprehensive Care

Introduction

Neal Shore, MD and Gordon Brown, DO

5 minutes

The Role of Apalutamide in mHSPC

Kim N. Chi, MD

10 minutes

The Role of Enzalutamide in mHSPC

Jeff Holzbeierlein, MD

10 minutes

The Role of ADT as the Backbone of Treatment

Bertrand Tombal, MD

10 minutes

The Role of Docetaxel + ADT in the Treatment of mHSPC

Christopher Sweeney, MD

10 minutes

Considerations in The Selection of ADT

E. David Crawford, MD

10 minutes

Conclusion

Neal Shore, MD and Gordon Brown, DO

5 minutes

Description:

ADT monotherapy is no longer considered the standard of care in men newly diagnosed with metastatic prostate cancer. Urologists should have a full understanding of highest level of evidence supporting combination therapies for mCSPC and an understanding of treatment options and specific management concerns. This program will close the gaps in practice by improving knowledge and competence about the role and impact of the new therapeutics to optimize care for patients diagnosed with androgen sensitive metastatic prostate cancer.

Desired Outcomes:

As a result of this program urologists will be able to better understand and implement combination therapies to optimally manage patients with androgen sensitive metastatic prostate cancer.

Learning Objectives:

At the conclusion of this activity participants will be able to:

- Describe new therapeutic options of the care in men with androgen sensitive metastatic prostate cancer.

- Identify appropriate therapeutic options for patients with androgen sensitive metastatic prostate cancer.

References:

Shore, N, Wallis, C. Efficacy of Enzalutamide + ADT in Metastatic Hormone-sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. Presented at the 2020 American Society of Clinical Oncology Virtual Annual Meeting. May (2020).

<https://www.urotoday.com/conference-highlights/asco-2020/asco-2020-prostate-cancer/121847-asco-2020-efficacy-of-enzalutamide-adt-in-metastatic-hormone-sensitive-prostate-cancer-by-pattern-of-metastatic-spread-arches-post-hoc-analyses.html>

Ng, K, Smith, S, Shamash, J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. *Oncology and Therapy*. June (8) (2020).

<https://link.springer.com/article/10.1007/s40487-020-00119-z>

Rathkopf, D, Scher, H. Apalutamide for Treatment of Prostate Cancer, *Expert Review of Anticancer Therapy*. 18 (9). <https://doi.org/10.1080/14737140.2018.1503954>